6. Recent Developments — 2025 & 2026

The landscape has moved meaningfully since the core research in sections 1–5 was published. Here's what's happened in the last 12 months.

Timeline of major 2025–2026 events

The Skrmetti decision and US state-by-state landscape

What this means practically as of May 2026:

• 25+ US states have bans on puberty blockers and/or cross-sex hormones for minors. (Bans in Montana and Arkansas remain permanently blocked by separate court orders.)
• The legal map is fragmented — what's available in one state may not be available across state lines. Families in restrictive states sometimes travel to permissive states; this is a documented pattern.
• Future legal challenges will likely route through the Americans with Disabilities Act (ADA) rather than equal protection, since the Skrmetti majority acknowledged that gender dysphoria is a recognized medical condition.
• The Trump administration's HHS released a 2025 report (see Section 1) that reinforced the legal direction — though the report was disputed by AAP and APA.

The first detransitioner malpractice verdict

Why this matters beyond the individual case:

• Establishes legal precedent that clinicians can be liable for inadequate assessment and consent in adolescent gender medicine. Plaintiff-side attorneys are now actively recruiting detransitioner clients.
• Camille Kiefel's separate $3.5M lawsuit settled confidentially in 2025 — that case alleged she was referred for a double mastectomy after only two brief appointments.
• Other major detransitioner suits are working through state courts (Chloe Cole's case in California; others in Missouri, Florida, North Carolina).
• The malpractice exposure is changing clinical behavior. Several US clinics quietly tightened their assessment protocols in 2024–2025 even where state law didn't require it.

The American Society of Plastic Surgeons position change

The ASPS reversal is structurally important because it fractures the previously unified front of major US medical organizations supporting the affirmative model. Estimated 1,000+ mastectomies for minors with gender dysphoria were being performed annually in the US before the position statement — that number will likely drop sharply now that the field's primary specialty organization explicitly opposes the practice.

The City Journal headline summed up the structural significance: "No consensus among medical groups on 'gender-affirming care' for minors" — the institutional consensus claim, long used to defend the affirmative model, no longer holds.

The Ruuska Finnish register study (April 2026) — possibly the most important new evidence

This is potentially a landmark study for several reasons:

• The largest controlled sample to date — over 18,000 individuals total with matched-control methodology.
• Long follow-up — minimum two years post-clinic-contact, which is meaningfully longer than most published outcome studies.
• Population-based registry data — Finland's national health registry catches everyone, addressing the "lost to follow-up" problem that has plagued earlier studies.
• Directly tests the "lifesaving care" claim — and finds that mental-health outcomes are worse, not better, after gender clinic contact. This contradicts the strongest argument that has been used to justify the affirmative model.
• Comes from Finland — the country with the longest data set of standardized gender clinic care, by clinicians who originally implemented the Dutch protocol.

It will take time for this study to be fully digested and critiqued, but it represents the strongest empirical challenge yet published to the claim that medical transition delivers mental-health benefits in the adolescent cohort. Defenders of the affirmative model will point out that "psychiatric morbidity after contact with the clinic" includes the comorbidities that exist independent of gender, and that the sicker patients are more likely to seek gender clinic help in the first place. These are legitimate methodological points, but the matched-control design was specifically built to address them.

Texas Children's Hospital settlement and the first US detransition clinic

The structural significance: detransitioners have struggled for years to find clinicians willing to help them (the Vandenbussche survey covered in Section 4 documented this extensively). A dedicated, well-funded detransition clinic at a major children's hospital both validates the existence of the patient population and creates a model other institutions may follow.

NHS England — Cass implementation progress

The UK continues to implement the Cass Review's recommendations:

• Two new NHS Children and Young People's Gender Services opened in April 2024 (Great Ormond Street Hospital in London, Alder Hey in Liverpool). A Bristol service became operational by November 2024.
• Up to six total regional centers will be operational by end of 2026, under a "fundamentally different clinical model" emphasizing multi-disciplinary mental-health-led care.
• The UK clinical trial on puberty blockers (PATHWAYS) was delayed from 2025 to 2026 over ethics concerns about the original trial design. Recruitment status as of May 2026 is uncertain.
• NHS England has also commissioned a review of adult gender services — a sign that the cautious reframing is extending beyond just the pediatric population.

The English approach now stands in clear contrast to current US practice in states without bans, and is being studied by health systems in Canada, Australia, New Zealand, and several European countries considering similar reforms.

The "peak trans" question — is youth identification declining?

Several US surveys since 2023 have shown a plateau or decline in adolescent and young adult trans identification — a pattern critics of the affirmative model long predicted would emerge once the cultural wave crested. The pattern is most visible in:

• Generation Z survey data showing a drop in "transgender or nonbinary" identification among 18–25-year-olds between 2022 and 2025.
• Some US pediatric gender clinics reporting decreased referral volumes (anecdotal at this point — not yet systematically published).
• Survey data showing changing attitudes among Gen Z toward both medical transition for minors and the broader affirmative framework.

This is consistent with the historic pattern for socially-mediated phenomena (compare: the eating-disorder peak of the 1990s, the recovered-memory peak of the 1980s, the DID peak of the 1980s, the TikTok tics peak of 2021–2022). If trans identification in youth follows the same pattern, it would be expected to continue declining for several years before stabilizing at a lower baseline.

The data on this is still emerging and the trend is not uncontroversial — some advocates dispute the methodology of the surveys showing decline. But the trajectory is worth monitoring.

What hasn't changed

For balance — several things that have not meaningfully shifted in 2025–2026:

• Major US medical associations (AAP, APA, Endocrine Society, AMA, American Academy of Child and Adolescent Psychiatry) continue to formally support the affirmative model for adolescent gender dysphoria, though several are conducting systematic evidence reviews that may eventually update their positions. The AAP authorized such a review in August 2023; it is ongoing.
• WPATH Standards of Care v8 (2022) remains the current version. The WPATH Files leak (March 2024) revealed internal acknowledgment by WPATH members of evidence gaps and risks — but the public-facing guidance has not been revised. WPATH continues to recommend medical transition pathways for adolescents without specific age minimums.
• The clinical / academic / political divide remains stark. US medical organizations and many academic researchers continue to dismiss the European systematic reviews, ROGD, and the detransitioner literature as politicized. The cautious-camp clinicians and the systematic reviewers continue to argue the affirmative-model defenders are minimizing serious evidence problems.